Search Results - Giuseppa Maltese
- Showing 1 - 3 results of 3
-
1
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial by Domenica Lorusso, Giovanni Scambia, Sandro Pignata, Roberto Sorio, Giulia Amadio, Stefano Lepori, Anna Maria Mosconi, Carmela Pisano, Giorgia Mangili, Giuseppa Maltese, Roberto Sabbatini, Grazia Artioli, Teresa Gamucci, Marilena Di Napoli, Ettore Capoluongo, Vienna Ludovini, Francesco Raspagliesi, Gabriella Ferrandina
Published 2015Artigo -
2
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 t... by Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Daniela Sambataro, Stefano Tamberi, Saverio Cinieri, Anna Maria Mosconi, Michele Orditura, Alba A. Brandes, Valentina Arcangeli, Pierluigi Benedetti Panici, Carmela Pisano, Sabrina Chiara Cecere, Marilena Di Napoli, Francesco Raspagliesi, Giuseppa Maltese, Vanda Salutari, Caterina Ricci, Gennaro Daniele, Maria Carmela Piccirillo, Massimo Di Maïo, Ciro Gallo, Francesco Perrone
Published 2015Artigo -
3
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome by Sabrina Chiara Cecere, Gaia Giannone, Vanda Salutari, Laura Arenare, Domenica Lorusso, Graziana Ronzino, Rossella Lauria, Gennaro Cormio, Claudia Carella, Paolo Scollo, Viola Ghizzoni, Francesco Raspagliesi, Marilena Di Napoli, E. Mazzoni, Cláudia Marchetti, Alice Bergamini, Michele Orditura, Giorgio Valabrega, Giovanni Scambia, Giuseppa Maltese, Elisabetta De Matteis, Cinzia Cardalesi, Vera Loizzi, Serena Maria Boccia, Emanuele Naglieri, Giuseppa Scandurra, Sandro Pignata
Published 2019Artigo
Search Tools:
Related Subjects
Cancer
Chemotherapy
Internal medicine
Medicine
Oncology
Ovarian cancer
BRCA mutation
Environmental health
Gene
Population
Progression-free survival
Astrobiology
Biochemistry
Biology
Chemistry
Clinical endpoint
Confidence interval
Discontinuation
Genetics
Genotype
Hazard ratio
Olaparib
Paclitaxel
Pathology
Pazopanib
Physics
Poly ADP ribose polymerase
Polymerase
Progressive disease
Randomized controlled trial